Jilin Aodong Pharmaceutical Group Co., Ltd. (SHE:000623)
China · Delayed Price · Currency is CNY 18.54
+0.75 (4.22%)
Apr 28, 2026, 3:04 PM CST
SHE:000623 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,316 | 2,537 | 3,404 | 2,850 | 2,263 |
Other Revenue | 18.7 | 73.86 | 45.58 | 17.95 | 41.05 |
| 2,335 | 2,611 | 3,449 | 2,868 | 2,304 | |
Revenue Growth (YoY) | -10.55% | -24.31% | 20.25% | 24.50% | 2.31% |
Cost of Revenue | 1,271 | 1,602 | 1,768 | 1,417 | 1,111 |
Gross Profit | 1,064 | 1,008 | 1,681 | 1,451 | 1,193 |
Selling, General & Admin | 1,086 | 1,055 | 1,354 | 1,181 | 1,093 |
Research & Development | 101.91 | 82.2 | 124.98 | 85.68 | 49.42 |
Other Operating Expenses | 41.72 | 37.28 | 46.43 | 42.77 | 39.3 |
Operating Expenses | 1,230 | 1,169 | 1,546 | 1,321 | 1,187 |
Operating Income | -165.14 | -160.4 | 134.53 | 129.91 | 5.87 |
Interest Expense | -52.26 | -92.08 | -144.35 | -142.99 | -130.49 |
Interest & Investment Income | 2,595 | 1,877 | 1,382 | 1,697 | 2,070 |
Other Non Operating Income (Expenses) | -1.32 | 7.42 | -10.77 | 589.79 | -7.62 |
EBT Excluding Unusual Items | 2,377 | 1,632 | 1,361 | 2,274 | 1,937 |
Gain (Loss) on Sale of Investments | 173.86 | -121.67 | -111.06 | -632.66 | -259.53 |
Gain (Loss) on Sale of Assets | 1.32 | -0.67 | 36.16 | 3.16 | -0.94 |
Asset Writedown | -183.01 | -65.33 | -3.25 | -1.25 | -2.84 |
Other Unusual Items | 51.88 | 77.54 | 217.25 | 77.92 | 92.6 |
Pretax Income | 2,421 | 1,521 | 1,500 | 1,721 | 1,767 |
Income Tax Expense | 59.32 | 2.23 | 55.83 | -80.16 | -4.19 |
Earnings From Continuing Operations | 2,361 | 1,519 | 1,444 | 1,801 | 1,771 |
Minority Interest in Earnings | 33.97 | 32.2 | 15.54 | -20.2 | 9.64 |
Net Income | 2,395 | 1,551 | 1,460 | 1,781 | 1,781 |
Net Income to Common | 2,395 | 1,551 | 1,460 | 1,781 | 1,781 |
Net Income Growth | 54.39% | 6.27% | -18.02% | 0.02% | 4.19% |
Shares Outstanding (Basic) | 1,173 | 1,177 | 1,125 | 1,135 | 1,139 |
Shares Outstanding (Diluted) | 1,173 | 1,177 | 1,295 | 1,301 | 1,259 |
Shares Change (YoY) | -0.34% | -9.08% | -0.46% | 3.36% | -1.39% |
EPS (Basic) | 2.04 | 1.32 | 1.30 | 1.57 | 1.56 |
EPS (Diluted) | 2.04 | 1.32 | 1.23 | 1.47 | 1.51 |
EPS Growth | 54.91% | 7.39% | -16.35% | -2.93% | 5.70% |
Free Cash Flow | 143.81 | -214.5 | -351.46 | 152.89 | 11.54 |
Free Cash Flow Per Share | 0.12 | -0.18 | -0.27 | 0.12 | 0.01 |
Dividend Per Share | 0.500 | 0.500 | 0.600 | 0.300 | 0.300 |
Dividend Growth | - | -16.67% | 100.00% | - | 50.00% |
Gross Margin | 45.58% | 38.62% | 48.74% | 50.59% | 51.76% |
Operating Margin | -7.07% | -6.14% | 3.90% | 4.53% | 0.26% |
Profit Margin | 102.57% | 59.43% | 42.33% | 62.09% | 77.29% |
Free Cash Flow Margin | 6.16% | -8.22% | -10.19% | 5.33% | 0.50% |
EBITDA | 25.92 | 46.62 | 339.83 | 326.49 | 200.39 |
EBITDA Margin | 1.11% | 1.79% | 9.85% | 11.38% | 8.70% |
D&A For EBITDA | 191.06 | 207.02 | 205.3 | 196.58 | 194.53 |
EBIT | -165.14 | -160.4 | 134.53 | 129.91 | 5.87 |
EBIT Margin | -7.07% | -6.14% | 3.90% | 4.53% | 0.26% |
Effective Tax Rate | 2.45% | 0.15% | 3.72% | - | - |
Revenue as Reported | 2,335 | 2,611 | 3,449 | 2,868 | 2,304 |
Advertising Expenses | 224.18 | 183.98 | 277.99 | 202.59 | 160.73 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.